Company / R&D per Share
GT Biopharma, Inc. R&D per Share History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.41
FY2020
5-year range
$0.00 / $9.36
FY2016-FY2020
Trend
-95.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $0.42 to $0.41 over the past 4 years.
Based on SEC 10-K filings.
0.41 in FY2020 with a 3-year CAGR of -64.9%.
Declined from $0.42 to $0.41 over the past 4 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -64.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, r&d per share decreased 95.7% year-over-year.
- Peak r&d per share was recorded in FY2017.
- Lowest r&d per share in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $0.41 | -95.7% |
| FY2017 | $9.36 | +2145.3% |
| FY2016 | $0.42 | - |
| FY2015 | $0.00 | - |
| FY2014 | $0.00 | - |
| FY2013 | $0.00 | -100.0% |
| FY2012 | $0.00 | -94.7% |
| FY2011 | $0.00 | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026